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Background: To validate a rapid questionnaire as a screening tool, because application of the diagnostic
revised criteria of the ICHD-II for medication overuse headache (MOH) requires experience for the physician
and is time-consuming.
Methods: ICHD-II criteria for probable MOH (pMOH) were transformed in questions formulated in such a way
that they could be self-administered, easily understood, and quickly filled out. We compared this questionnaire
to the gold standard: the diagnosis made by headache specialists, based on the the ICHD-II criteria. Patients
who were consulting for pMOH or migraine for the first time were consecutively included. As validity
indicators, we calculated sensitivity, specificity, positive and negative predictive values of the items.
Results: Seventy-nine patients were screened, 77 included, 2 female patients excluded. Forty-two patients have
been considered as suffering from pMOH, 35 patients suffered from migraine without medication overuse. The
association of the question “do you take a treatment for attacks more than 10 days per month” and the
question “is this intake on a regular basis?” had a sensitivity of 95.2% and a specificity of 80%.
Conclusion: This screening tool can detect pMOH with a sensitivity that could be of interest to screen patients
in clinical practice and to pre-include patients for research as epidemiological studies.
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The prevalence of chronic daily headaches with medica-
tion overuse is around 1.5% of the general population,
with prevalence figures being very similar across differ-
ent countries. They account for 10% to 78% of patients
seen in headache centres [1]. Medication overuse headache
(MOH) decreases the quality of life and accounts for re-
duced efficiency at work. Population-based and clinical data
reflects the importance of this public health problem [2].
The 2nd edition of the International classification of
headache disorders (ICHD-II) defined MOH as a migraine-
type headache:1 present on ≥15 days per month with at
least 1 of the following characteristics: bilateral, pressing/* Correspondence: virginie.dousset@chu-bordeaux.fr
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in any medium, provided the original work is ptightening quality, mild or moderate intensity; [3] associated
with use of acute treatment for headache on a regular basis
for more than 3 months [1] that developed or markedly
worsened during medication overuse [4] that resolved or
reverted to its previous pattern within 2 months after
discontinuation of the offending medication [5]. Subse-
quent revision proposed to eliminate the headache
characteristics [3] and to delete the last criterion in
order to allow the establishment of MOH diagnosis
when the patient suffers from the disorder and not
only after the medication withdrawal [4]. This change
suggested by Olesen has not been officially implemented
and correct formulation for MOH before withdrawal
should be probable MOH (pMOH). The IHS classification
is an explicit clinical criterion so that the diagnosis of
pMOH does not require any specific examination that is
needed only to exclude a symptomatic origin. Applicationan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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II allows making the diagnosis on the basis of consump-
tion of medication (number of days monthly) and a
worsening of the headache during the time of medication
intake. However, this clinical diagnosis with a face-to-face
interview is the gold standard and requires clinical experi-
ence for the physician, and enough time to question pa-
tients precisely, to specify ICHD-II criteria, and to specify
the diagnosis of primary headache, more frequently mi-
graine, which has been the basis for the development of
the MOH. This is time-consuming.
In this clinical context, a less time consuming tool
would be of interest. We have developed a 4 item ques-
tionnaire evaluating the frequency of headaches and the
amount of medication consumption used to treat the at-
tacks and compared sensitivity and specificity of this in
migraine patients and MOH patients. Indeed, such a tool
would be useful in clinical practice and for research, to
pre-include patients for epidemiological studies.Methods
Design
We evaluated the accuracy of the rapid evaluation of
headaches and medication used to treat the attacks con-
sumption in a sample of consecutive headache patients
seen at the Bordeaux Headache Centre for their first
visit. Our goal was to establish the validity of a brief
screening instrument that uses among other things self-
reporting of use of acute treatment for headache by the
patient and has both the sensitivity and specificity that
would make it useful in the outpatient headache centres,
and in general practitioner practices. The validity study
required the comparison of answers of medication over-
use headache sufferers to the answers of migraine suf-
ferers, with the gold standard diagnosis done by two
neurologists specialised in headache. The study was
conducted in France in the Bordeaux headache centre.
Because the setting of intended use was at first pain or
headache centres, our validation study occurred in an
outpatient headache centre (a specialized headache
centre of a teaching hospital).Table 1 ICHD-II criteria for PMOH and self questionnaire
ICHD-II criteria for probable MOH
A. Headache present on ≥ 15d/month
B. Regular overuse for > 3 months
1. Ergotamine, triptans, opioids or combination analgesic medications o
on a regular basis for 3 months
2. Simple analgesics or any combination of ergotamine, triptans, analge
on ≥15 D per month on a regular basis for > 3 months
C. Headache has developed or markedly worsened during medication overuPatients
All men and women aged 18 years or more who were
visiting for migraine or probable MOH identified by
their general practitioner were consecutively pre in-
cluded. Pre inclusion required the ability to read and
write French. They filled out the questionnaire in the
waiting room. Then definitive inclusion was done after
the diagnosis of migraine without aura or migraine with
aura, or migraine without or with aura plus pMOH by
one of the headache specialist during the face-to-face
interview according to the 2004 ICHD-II [3] criteria.
Other primary headaches or secondary headaches were
exclusion criteria. Patients were enrolled after providing
their informed consent. We did not collect any personal
information so that an ethics vote was not necessary.Questionnaire elaboration
The criteria defined pMOH as (A) headache present
on ≥15 days per month, (B) associated with use of
acute treatment for headache on a regular basis for
more than 3 months ; (C) that developed or markedly
worsened during medication overuse; (D) medication
overuse is defined as 10 days or more of intake in
triptans, ergot alkaloids, mixed analgesics or opioïds,
and 15 days or more of analgesics/NSAIDs or the com-
bined use of more than one substance. These criteria
were transformed into questions by experts of MOH.
They were formulated in such a way that they could be
self-administered, quickly filled out and easily under-
stood. The questions were: 1. Do you have headaches
for more than 15 days/month? 2. Do you take treat-
ment for attacks more than 10 days per month? 3. Is it
for more than 3 months? 4. Is drug intake regular?
(Table 1). The Item C of ICHD-II criteria (the head-
ache worsened with the overuse of the acute medica-
tions) has been marked out because it’s a difficult
question for the patients who answered about the in-
take of the medication to relieve the headache. In
order to verify that all questions could be easily under-
stood, we submitted the questionnaire to a sample of
patients before beginning the study. Questions should haveSelf-questionnaire
1. Do you have headache on ≥ 15 days per
month?
2. Do you take a treatment for attacks
on ≥ 10 days per month?
n ≥ 10 days /month 3. For more than 3 months?
sics opioids 4. Is this intake on a regular basis?
se
Table 2 Age, sex and onset for migraine patients and
pMOH* patients
Migraine MOH P value†
n = 35 % n = 42 %
Age (years) 37.4 13.6 46.7 12.2 0.003
Male 13.0 37.1 8.0 19.0 0.060
Female 22.0 62.9 34.0 81.0
Onset (years)
< 10 years
>10 years 10.0 28.6 19.0 45.2 NA
25.0 71.4 23.0 54.8 NA
Drug intake
Acetaminophen or NSAID 2 25 6 17.6
Combination 2 25 12 20.6
Triptans 0 9 35.3
Ergots opioids 1 12.5 0 26.5
2 25 12 35.3
*probable Medication overuse headache.
†Comparison of means in student’s test.
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and sufficient specificity to minimize the number of pa-
tients who screen positive for MOH but do not have the
condition. This tool must not be time-consuming or bur-
densome for routine investigation in pain clinics. Before
the face-to-face with the neurologist, the nurse of the head-
ache centre gave the questionnaire to the patients. The first
step of the study was that each of the patients filled out the
questionnaire unaided, and unknown to the neurologist.
Then the face to face consultation was realized, the neur-
ologist didn’t know the answers of the patient to the ques-
tionnaire during the face to face interview. The same
procedures were used in both groups.
The gold standard used to test the validity of the ques-
tionnaire was the face to face diagnosis of probable MOH
made by headache specialists, based on the second edition
of the ICHD-II. The gold standard procedure included a
medical history, a comprehensive neurological history and
examination. Possible organic causes of headache were ex-
cluded through a general and a neurological examination
and if needed complementary exams. The headache spe-
cialist completed a symptom checklist based on ICHD-II
criteria and assigned a clinical diagnosis of migraine or
migraine plus MOH.
Validity assessment and data analysis
Filling out the questionnaire and the face to face inter-
view were done the same day. As validity indicators, we
calculated sensitivity, specificity and the positive and
negative predictive values for each pair, trio of item and
for the 4 items. The sensitivity corresponded to the per-
centage of all affirmative answers in the group of pa-
tients with MOH (ability of detection of MOH cases).
The specificity corresponded to the percentage of nega-
tive answers in the group of subjects with migraine (abil-
ity of detection of non-suffering MOH patients). The
positive predictive value corresponded to the percentage
of patients with MOH who screened positive. The nega-
tive predictive value corresponded to the percentage of
patients without MOH who screened negative. Data ana-
lysis was done using SAS 8.2 for windows.
Results
Patients were enrolled between September 2009 and
December 2009. Eighty-nine patients have been seen for
headache in the headache centre during this period.
Seventy-seven patients were pre-included, with twenty-
one men (27.3%) and fifty-six women (72.7%). Ages varied
from 16 to 71 years, with mean age of 42.5.
After being interviewed by the neurologists, 42 pa-
tients (55%) have been considered as suffering from
probable MOH, 35 patient having migraine without
medication overuse. There were more women with
probable MOH than men (60.7% vs. 39.3% p = 0.08).The mean age in pMOH group was higher than in
migraine group (46.7 (12.2) years vs. 37.4 (13.6) years,
p = 0.002). Patients were heterogeneous concerning
the duration of the disease and concerning the kind
of medication they overused (Table 2).
Next we determined sensitivity, specificity, positive
predictive value, negative predictive value for each item,
for each pair of item and for the items 1 + 2 + 4.
The third question about the onset and duration of
the drug intake was clearly not discriminating enough:
90.5% of patients have answered yes to the third ques-
tion, that’s why item 3 has been marked out. Results are
showed in Table 3.
Concerning patients with pMOH, 19 patients had a dur-
ation of medication overuse > 10 years, 13 patients up to
10 years. Duration of pMOH didn’t have any influence on
answers to questions. Twenty-four patients had pMOH
type 1 as mentioned Saper and Lake [6], 18 type 2. This
had no impact on answers. Eight patients overused acet-
aminophen or NSAID, 10 overused an association of med-
ications, 14 overused combinations, 9 overused triptans
and one ergotamine. The size of the sample did not allow
to study the impact of the type of medication on the re-
sponse profile. Duration of pMOH and classification of
pMOH type 1 or 2 had no impact on answers to question-
naire (p = 0.07 and p = 0.01 respectively).
Discussion
The main results of our study validation was the follow-
ing: the association of question 2 (do you take a treat-
ment for attacks more than 10 days per month?) and
question 4 (is this intake on a regular basis?) had a
Table 3 Sensitivity, specificity, positive predictive values, negative predictive values for each item and for more than
one item
Question Sensitivity Specificity PPV* NPV**
Absolute values % Absolute values % Absolute Values % Absolute values %
1 34/42 81.0 29/34 85.3 34/49 87.2 29/37 78.4
2 40/42 95.2 26/34 76.5 40/48 83.3 26/28 92.9
3 40/41 97.6 6/33 18.2 40/67 59.7 6/7 85.7
4 41/42 97.6 12/35 34.3 41/64 64.1 12/13 92.3
Yes for each question
1 + 2 34/42 81.0 33/34 97.1 34/35 97.1 33/41 80.5
1 + 4 35/43 81.4 34/35 97.1 34/35 97.1 34/42 81.0
2 + 4 40/42 95.2 28/35 80.0 40/47 85.1 28/30 93.3
1 + 2 + 4 34/42 81.0 35/35 100.00 34/34 100.00 35/43 81.4
*positive predictive value.
**negative predictive value.
Table 4 Answers to the question concerning the criteria
specifying the necessity of having developed a
worsening of the headaches during overuse: results of
the pilot study in 10 patients suffering from pMOH
Patient Understanding of the
question (Yes/No)
Answer to the question
n° 1 Yes No, because had tried to decrease
the intake as early as the worsening
of headaches
n° 2 Yes Doesn’t know
n° 3 Yes No
n° 4 Yes Yes
n° 5 Yes Yes
n° 6 Yes No
n° 7 Yes Doesn’t know
n° 8 Yes Yes
n° 9 Yes No
n° 10 Yes No, because already tries to decrease
drug consumption
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tages of such questions are their simplicity, rapidity, and
low cost. Our sample of migraineurs, and of pMOH suf-
ferers were heterogeneous in terms of age, sex, and dur-
ation. Moreover, we kept equivocal cases.
Several limitations of the results have to be discussed:
At first, possible selection bias could exist: in a tertiary
centre, patients could have a better knowledge of their
disease, and could answer easier yes to the different
questions, with better understanding, and therefore
would be more able to quantify their medication intake.
That could increase positive answers and then explain
an increase of their sensibility in a tertiary centre. More-
over, patients seeking care in tertiary centres could have
more severe disease, more severe medication overuse
leading again to an increase in the questionnaire sensibil-
ity. For these reasons, generalisability to a population-
based setting need to be further tested. Secondly problems
with the measures have to be considered: concerning the
construction of the questionnaire, the criteria specifying
the necessity of having developed a worsening of the
headaches during overuse was not kept. Indeed, patients
usually answered that if they take medication, it is because
they have headaches and not the opposite [7]. Patients
usually think that medication overuse is the result of an
unrecognized or inadequate treatment of a primary head-
ache disorder. Moreover it is a retrospective question,
about a period sometimes many years before the diagnosis
of pMOH. However, to evaluate the reliability of
transforming the criteria of having developed a wors-
ening of the headaches during overuse , we did a pre-
test in a sample of 10 patients, asking them if they
have developed worsening of the headaches during
overuse asking them if they understood the question.
The results of this pretest are shown in Table 4. Five
patients answered that they didn’t develop a worsening
of headaches during overuse, 2 patients answered thatthey did not know. That’s why this criterion was not
kept. In the same way, we evaluated the ability to
understand the other questions by the patients. Are ex-
pressions such as treatment for attacks intake on a
regular basis easily understandable for patients without
any medical knowledge? We did a second pilot study
on a sample of 24 patients testing the comprehensibil-
ity of both these expressions: namely the expression
treatment for attack was understood by 22 patients.
The expression “intake on a regular basis” was under-
stood by all, except one patient. At the end, if we do
the hypothesis on a decrease of sensitivity in the gen-
eral population, what could be the outcome of false
positives, i.e. patients with an intake below 10 days per
month, on the border of medication overuse: could it
Table 5 Methods used to diagnose MOH in main epidemiological studies
Author Country Population Questions or criteria MOH Diagnosis Type of questionnaire




1- Have you ever had headache?
2- Do you have headache tend days or more per month?
Wang 2000 Taiwan Population of a small islet > 65
years-old
Revision HIS criteria proposed by Silberstein Person-to-person survey
method and diagnosis by a
neurologist
Unvalidated Questionnaire
Lu 2001 Taiwan Random population based survey Face-to face questionnaire Then face-to-face diagnosis
with a physician
Unvalidated questionnaire
Headache being present for more than 3 days per week
in the previous year
Colas 2004 Spain Quota sampling approach > 14 Have you ever had headache? Then face-to-face diagnosis
with a physician
Unvalidated questionnaire
Do you have headache 10 or more days per month?
If yes, to other questions: In the last three months have you
taken any analgesic for your head pain
Hagen 2009 Norway All inhabitants of a county of
Norway invited to answer to a
questionnaire
Headache more than 14 days per month and use of analgesics
4 times per week or more




Straube 2010 Germany Adults from 3 German regions 14 single items designed to assess the 2nd ed of IHS, medication
overuse classified based on medication intake during the last month.
Face-to-face by trained
interviewers
Kappa statistics was calculated:
94.5% indicating excellent inter-rater
agreement
Jonsson 2011 Sweden Randomized cluster sampling Two screening questions: headache present on ≥ 15 days per month
and using medication for≥ 10 days per month during the past
three months
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classified as having pMOH by the questionnaire? In
fact, it could have positive repercussions for the pa-
tients, with a primary or secondary preventive effect
on the risk of developing pMOH. Concerning false
negative patients, they will continue their overuse,
until they see a neurologist or another physician. In
our study, sensitivity and specificity could be high because
of the sole inclusion of migraine sufferers, without includ-
ing other primitive headaches, such as cluster headache
and tension-type headaches. But, for a pilot study, it is ac-
ceptable to have included only migraine patients and CH
frequency in tertiary centre only. What improvements
does this questionnaire have in comparison to other pub-
lished questionnaire: Table 5 presents data about the
methods used in main epidemiological studies concerning
MOH [5,8-13]. For each study, we specified the questions
or criteria used for the MOH diagnosis, and specified if
these questions were validated or not. One can notice that
the only author using a validated questionnaire was Hagen
[14]. In the general population he determined the diagnos-
tic performances of the association of 2 questions: head-
aches which are present for more than 14 days per month
and the use of analgesics 4 times per week or more.
With such an association, a lower sensitivity was
found: 75%, specificity was 100%. Other questionnaires
do exist [14-17], but they concern research on dependence
[15,16]. Radat et al. [15] constructed and validated a ques-
tionnaire measuring dependence on analgesics and on mi-
graine treatments in headache patients. It measures with
21 questions a global dimension of dependence in MOH
sufferers, but does not allow for giving a cut-off on which
patients should be considered to have MOH. Such a de-
pendence questionnaire which focus on the dimension of
dependence are more time-consuming, and maybe more
difficult to administrate in current care, neither in tertiary
nor in primary care settings. Maizels in 2003 [18] pro-
posed a paradigm for the clinical application of a brief
headache screening tool. Questions were open and medi-
cation overuse was correctly identified in 86% of patients
with a specificity of 79%. In this context, the advantages of
this screening tool are its shortness, it’s easy administra-
tion without much paper work and low cost. We must
consider its diagnostic performances outside tertiary
centre, i.e. neurologists outside hospitals, general practi-
tioners, and maybe for patients themselves outside of any
health place. In particular, predictive values have to be de-
termined in the general population. To conclude, we vali-
dated a screening tool in the French version for the
diagnosis of pMOH. In the future, an English version
should be validated.Competing interests
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